CKD to conduct Phase I trial for novel antidiabetic agent

Published: 2004-11-24 06:57:00

Updated: 2004-11-24 06:57:00

The Ministry of Health and Welfare said on November 22 that Chong Kun Dang Pharmaceutical Co. will conduct its Phase I trial for novel glitazone-based diabetes medication (code name: CKD-501) with the ministry's financial support of 740 million won for the recent five years.

Preclinical studies have indicated that CDK-501 is three times more effective for lowering blood sugar than convention...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.